Trial Data Triggers Massive Rally In Janux Therapeutics (NASDAQ:JANX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive results for its phase 1b CodeBreaK 101 trial and confirmed 30 percent objective response rate for its Amgen's Vectibix in a
However, in the Phase III PARADIGM trial, there was no difference in survival between the two arms when researchers focused only on patients with right-sided tumors.